1
Robert C Ladner, Sonia K Guterman, Bruce L Roberts, William Markland, Arthur C Ley, Rachel B Kent: Directed evolution of novel binding proteins. Protein Engineering, Iver P Cooper, June 29, 1993: US05223409 (1672 worldwide citation)

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore o ...


2
Robert C Ladner, Sonia K Guterman, Bruce L Roberts, William Markland, Arthur C Ley, Rachel B Kent: Viruses expressing chimeric binding proteins. Protein Engineering Corporation, Iver P Cooper, April 4, 1995: US05403484 (766 worldwide citation)

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore o ...


3
Robert C Ladner, Sonia K Guterman, Bruce L Roberts, William Markland, Arthur C Ley, Rachel B Kent: Directed evolution of novel binding proteins. Protein Engineering Corporation, Iver P Cooper, November 5, 1996: US05571698 (694 worldwide citation)

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore o ...


4
Arthur C Ley, Sonia K Guterman, William Markland, Rachel B Kent, Bruce L Roberts, Robert C Ladner: ITI-D1 Kunitz domain mutants as HNE inhibitors. Dyax, Wolf Greenfield & Sacks P C, July 18, 2006: US07078383 (9 worldwide citation)

Mutants of Kunitz domain 1 (ITI-D1) of human inter-α-trypsin inhibitor (ITI), are useful as inhibitors of human neutrophil elastase. Mutants characterized by one or more of the following substitutions (numbered to correspond to bovine pancreatic trypsin inhibitor, the archetypal Kunitz domain) are o ...


5
Bruce L Roberts, Jeffrey D Elliott, Ronnie L Hoskins, Bruce R Palmer: Process for preparing pigment dispersible in paints and plastics concentrates. Kerr McGee Chemical, C Clark Dougherty Jr, McAfee & Taft, April 8, 2003: US06544328 (6 worldwide citation)

A process for preparing an improved pigment which is readily dispersible in paints and plastics concentrates is provided. In accordance with the process, a particulate pigment is mixed with water to form a slurry thereof, and a surface active agent is mixed with the slurry so that the pigment therei ...


6
Bruce L Roberts, Srinivas Shankara, William Harold Brondyk, William M Siders: Anti-human CD52 immunoglobulins. Genzyme Corporation, Ropes & Gray, December 31, 2013: US08617554 (3 worldwide citation)

The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also ...


7
Bruce L Roberts, Srinivas Shankara, Charles A Nicolette: Genes differentially expressed in cancer cells to design cancer vaccines. Genzyme Corporation, Legal Department, February 14, 2002: US20020018766-A1 (1 worldwide citation)

The present invention calls utilized genes differentially expressed in target cells to design vaccines to generate an immune response. Unlike prior art methods that seek to identify antigenic proteins from phenotypic analysis, the subject method applies functional genomics for antigen identification ...


8
Bruce L Roberts, Charles Nicolette, Srinivas Shankara: Preparation and use of particulates composed of adenovirus particles. Genzyme Corporation, Legal Department, January 17, 2002: US20020006412-A1 (1 worldwide citation)

This invention provides particulates of adenoviral particles comprised of individual adenovirus virions complexed to an insoluble micro-platform material and for such compositions further comprised of a polynucleotide encoding an antigenic peptide. The invention further provides method for forming s ...


9
Johanne M Kaplan, Bruce L Roberts, William M Siders: Methods and compositions for treating lupus. GENZYME CORPORATION, Steptoe & Johnson, Z Ying Li, Wyan Ching M Lee, April 11, 2017: US09617343

The invention provides methods of treating lupus in a patient with an anti-CD52 antibody. Also includes are methods of increasing infiltration of regulatory T cells to affected sides of the patient's body, methods of reducing urine protein and/or albumin levels and methods of depleting lymphocytes t ...


10
Bruce L Roberts, Srinivas Shankara: Compositions and methods to diagnose and treat lung cancer. Genzyme Corporation, Legal Department, March 22, 2007: US20070065889-A1

The present invention provides methods for aiding in the diagnoses of the condition of a lung cell, and methods of screening for a potential therapeutic agents for cytolysis or apoptosis of lung cancer cells.